Leriglitazone

DB15021InvestigationalSmall molecule

Leriglitazone is under investigation in clinical trial NCT03917225 (A Clinical Study to Evaluate the Effect of MIN-102 on the Progression of Friedreich's Ataxia in Male and Female Patients).

Chemical structure of Leriglitazone
Mechanism
Curator reviewed
Formula / weight
C19H20N2O4S · 372.438 g/mol (avg)
Also known as
Hydroxypioglitazone
Code names
MIN-102

Resolves to

Compound
UNIIK824X25AYACAS146062-44-4ChEMBLCHEMBL1267ChEBI82937
Clinical / RWD
ATCA16AX23
Structure
InChIKeyOXVFDZYQLGRLCD-UHFFFAOYSA-NSMILESCC(O)C1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1
Targets
P37231PPARG

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
4Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1ATC codeIncluding every combination product, plus 4 drug categories
Sign in
3+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Leriglitazone, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In